C2 and acute myeloid leukemia: Limited studies have been done to investigate the effects of mTORC1/C2 inhibition in AML [14, 23], particularly, in AML stem/progenitor cells, often called leukemic stem cells, constituting a small population of leukemic cells capable of self-renewal that contributes to residual disease [24].